Navigation Links
Certain Painkillers Appear to Boost Odds for Heart Attack
Date:1/12/2011

By Steven Reinberg
HealthDay Reporter

TUESDAY, Jan. 11 (HealthDay News) -- Common painkillers taken to treat inflammation, such as Celebrex and Advil, can raise the risk of heart attack, stroke or death, a review of existing research suggests.

Swiss researchers analyzed the results of 31 trials involving seven non-steroidal anti-inflammatory drugs (NSAIDs), as these medications are called, and concluded that cardiovascular risk needs to be considered before prescribing any of them.

"NSAIDs are widely used worldwide for treating pain and inflammation," said Dr. Gregg Fonarow, American Heart Association spokesman and professor of cardiology at the University of California, Los Angeles.

"A number of studies have shown that many of these agents are associated with increased risk of cardiovascular events, particularly when used at higher doses and for longer periods of time, but uncertainty remains as to the magnitude of the risk and how the cardiovascular risk may vary among different NSAIDs," said Fonarow, who was not involved in the study.

All the NSAIDs studied increased the risk of cardiovascular events, but the magnitude of risk is small in absolute terms -- approximately one cardiovascular event per 100 patient-years of follow-up, Fonarow noted.

"In many patients the benefits provided by these agents may outweigh the risk, and other steps can be taken to reduce the patient's cardiovascular risk," he said.

The report is published in the Jan. 11 online edition of the BMJ.

In 2004, the drug Vioxx (rofecoxib), which belonged to a class of NSAIDs called COX-2 inhibitors, was pulled from the market because of its link to an increased risk of heart attack.

To explore the connection between NSAIDs and heart problems, a team led by Dr. Peter Juni, from the Institute of Social and Preventive Medicine at the University of Bern, reviewed 31 trials that included 116,429 patients. This method of reviewing trial findings to uncover a pattern is called a meta-analysis.

The painkillers the patients were taking included naproxen (Aleve), ibuprofen (Advil, Motrin), diclofenac (Voltaren, Cataflam), celecoxib (Celebrex), etoricoxib (Arcoxia), rofecoxib (Vioxx), lumiracoxib (Prexige) or placebo.

Overall, the number of heart events among patients taking NSAIDs was low, the researchers found. In 29 trials, 554 heart attacks occurred. In 26 trials, 377 strokes were reported, and in 28 trials, 676 people died.

Compared with patients taking placebo, those taking rofecoxib and lumiracoxib had twice the risk of heart attack, and those taking ibuprofen had more than three times the risk of stroke. The highest risks for cardiac death were associated with etoricoxib and diclofenac, where the risk was around four times greater than for placebo, the researchers found.

Naproxen appeared to be the least harmful medication, they noted.

"Our study provides the best available evidence on the safety of this class of drugs," the researchers wrote. "Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms. Cardiovascular risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug," they concluded.

Commenting on the study, Dr. Eric J. Topol, director of the Scripps Translational Science Institute and one of the experts who uncovered the risks associated with Vioxx, said a meta-analysis can leave many questions unanswered but is of value nonetheless.

"Pooling large data sets like this winds up with ambiguity as it homogenizes differences in patient population characteristics, dose of drugs, how endpoints were ascertained and when, etc.," he said. "I am not sure if the conclusions reflect or agree with other meta-analysis results," Topol noted.

"Despite the limitations, this study has made many excellent contributions on the NSAID issue, so we need to factor these into the mix," Topol said.

More information

For more information on NSAIDs, visit the U.S. Food and Drug Administration.

SOURCES: Eric J. Topol, M.D., director, Scripps Translational Science Institute, La Jolla, Calif.; Gregg Fonarow, M.D., American Heart Association spokesman, and professor, cardiology, University of California, Los Angeles; Jan. 11, 2011, BMJ, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Certain pain medications do not appear to be associated with skin cancer risk
3. AGA offers new recommendations for CRC surveillance for certain patients with IBD
4. Smoking significantly increases risk of aneurysm in people with certain genes
5. American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages
6. Certain Bone Drugs May Lower Breast Cancer Risk
7. Football Injuries More Likely on Certain Artificial Turf
8. Plavix Can Help Cut Death Risk in Certain Heart Patients
9. The Worst Is Over, but the Road to Growth Is Uncertain - The 17th Annual CFO Rising Conference & Exhibition
10. Perhaps a longer lifespan, certainly a longer health span
11. One in Five Parents Would Spank in Certain Settings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Painkillers Appear to Boost Odds for Heart Attack
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: ... published author, Sara Seymour, who lives in Lafayette, Indiana where she works in a ... iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book ...
(Date:1/19/2017)... (PRWEB) , ... January 20, 2017 , ... Today, the ... to participate in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who ... patients. APMs are an important part of the Administration’s effort to build a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... This month, the ... that the name of their drug rehab center in Delray Beach, Florida has been ... that not only stars such as Philip Seymour Hoffman and Chris Farley are dying ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
Breaking Medicine Technology: